Prostate neoplasm

Summary

Prostate neoplasm (MONDO:0021259) is a cancer (an umbrella term covering 5 Mondo subtypes) with 2 cohort genes (1 GWAS associations across 2 studies; 2 CIViC-evidence somatic drivers; 2 ClinVar predisposition records) and 106 clinical trials. Top therapeutic interventions include abiraterone acetate, dextromethorphan, and theophylline anhydrous.

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Cohort genes: 2
• GWAS associations: 1
• ClinVar variants: 2
• Clinical trials: 106

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prostate neoplasm
Mondo ID	MONDO:0021259
DOID	DOID:13206
NCIT	C3343
UMLS	C0033578
MedGen	18697
Anatomy (UBERON)	UBERON:0002367
Is cancer (heuristic)	yes

Also known as: neoplasm of prostate · neoplasm of prostate gland · neoplasm of the prostate · prostate gland neoplasm · prostate gland neoplasm (disease) · prostate gland tumor · prostate gland tumour · prostate tumor · prostate tumour · tumor of prostate · tumor of prostate gland · tumor of the prostate · tumour of prostate · tumour of prostate gland · tumour of the prostate

Data availability: 2 ClinVar variants · 1 GWAS association (2 studies).

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › prostate disorder › prostate neoplasm

Related subtypes (4): prostatic cyst, prostate calculus, prostatitis, benign prostatic hyperplasia

Subtypes (5): prostate neuroendocrine neoplasm, prostate intraepithelial neoplasia, prostate cancer, prostate phyllodes tumor, benign neoplasm of prostate

Genetics & variants

GWAS landscape

1 GWAS associations across 2 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr17:48728343	2e-22		T	4.51

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90079112	Backman JD	2021	8,498	24,727	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083098	Backman JD	2021	8,498	24,727	Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	0

Functional consequences

Consequence	Count
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr17:48728343				0.003			2e-22	Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

2 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
142795	NM_000059.4(BRCA2):c.3723T>G (p.Phe1241Leu)	BRCA2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
24934	NM_020975.6(RET):c.2071G>A (p.Gly691Ser)	RET	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 22 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7
RET	Act	ANGS,MEL,NSCLC,PGNG,SOFT_TISSUE,WDTC	CIViC #42

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
RET	Orphanet:146	Differentiated thyroid carcinoma
RET	Orphanet:1848	Renal agenesis, bilateral
RET	Orphanet:247698	Multiple endocrine neoplasia type 2A
RET	Orphanet:247709	Multiple endocrine neoplasia type 2B
RET	Orphanet:276621	Sporadic pheochromocytoma/secreting paraganglioma
RET	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
RET	Orphanet:388	Hirschsprung disease
RET	Orphanet:93100	Renal agenesis, unilateral
RET	Orphanet:99361	Isolated familial medullary thyroid carcinoma
RET	Orphanet:99803	Haddad syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	clinvar
RET	HGNC:9967	ENSG00000165731	P07949	Proto-oncogene tyrosine-protein kinase receptor Ret	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN,…

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
RET	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Cadherin-like_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	1
secondary oocyte	1
ventricular zone	1
dorsal root ganglion	1
substantia nigra pars compacta	1
substantia nigra pars reticulata	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
RET	193	broad	marker	substantia nigra pars reticulata, dorsal root ganglion, substantia nigra pars compacta

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRCA2	4,839
RET	4,203

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
RET	P07949	34
BRCA2	P51587	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 32. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Impaired BRCA2 translocation to the nucleus	1	1903.3×	0.008	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	1903.3×	0.008	BRCA2
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	475.8×	0.010	BRCA2
HDR through MMEJ (alt-NHEJ)	1	439.2×	0.010	BRCA2
Diseases of DNA Double-Strand Break Repair	1	407.9×	0.010	BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	407.9×	0.010	BRCA2
Resolution of D-Loop Structures	1	317.2×	0.010	BRCA2
Formation of the nephric duct	1	317.2×	0.010	RET
Diseases of DNA repair	1	285.5×	0.010	BRCA2
NPAS4 regulates expression of target genes	1	248.3×	0.010	RET
Formation of the ureteric bud	1	248.3×	0.010	RET
Impaired BRCA2 binding to PALB2	1	228.4×	0.010	BRCA2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	211.5×	0.010	BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	211.5×	0.010	BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	211.5×	0.010	BRCA2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	196.9×	0.010	BRCA2
Homologous DNA Pairing and Strand Exchange	1	190.3×	0.010	BRCA2
Homology Directed Repair	1	154.3×	0.010	BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	154.3×	0.010	BRCA2
Impaired BRCA2 binding to RAD51	1	154.3×	0.010	BRCA2
Resolution of D-loop Structures through Holliday Junction Intermediates	1	150.3×	0.010	BRCA2
Meiosis	1	142.8×	0.010	BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	1	135.9×	0.010	BRCA2
RET signaling	1	129.8×	0.010	RET
DNA Double-Strand Break Repair	1	124.1×	0.010	BRCA2
Reproduction	1	95.2×	0.012	BRCA2
HDR through Homologous Recombination (HRR)	1	95.2×	0.012	BRCA2
Meiotic recombination	1	64.9×	0.018	BRCA2
DNA Repair	1	49.2×	0.022	BRCA2
RAF/MAP kinase cascade	1	30.5×	0.035	RET

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
embryonic epithelial tube formation	1	4213.0×	0.004	RET
posterior midgut development	1	4213.0×	0.004	RET
mitotic recombination-dependent replication fork processing	1	4213.0×	0.004	BRCA2
positive regulation of metanephric glomerulus development	1	2808.7×	0.004	RET
ureter maturation	1	2106.5×	0.004	RET
Peyer’s patch morphogenesis	1	2106.5×	0.004	RET
GDF15-GFRAL signaling pathway	1	2106.5×	0.004	RET
negative regulation of mammary gland epithelial cell proliferation	1	1685.2×	0.004	BRCA2
establishment of protein localization to telomere	1	1053.2×	0.005	BRCA2
lymphocyte migration into lymphoid organs	1	936.2×	0.005	RET
response to UV-C	1	842.6×	0.005	BRCA2
telomere maintenance via recombination	1	766.0×	0.005	BRCA2
positive regulation of extrinsic apoptotic signaling pathway in absence of ligand	1	766.0×	0.005	RET
positive regulation of cell size	1	648.1×	0.005	RET
glial cell-derived neurotrophic factor receptor signaling pathway	1	601.9×	0.005	RET
regulation of DNA damage checkpoint	1	561.7×	0.005	BRCA2
membrane protein proteolysis	1	526.6×	0.005	RET
positive regulation of cell adhesion mediated by integrin	1	526.6×	0.005	RET
inner cell mass cell proliferation	1	495.6×	0.005	BRCA2
neuron cell-cell adhesion	1	495.6×	0.005	RET
enteric nervous system development	1	495.6×	0.005	RET
centrosome duplication	1	468.1×	0.005	BRCA2
response to X-ray	1	443.5×	0.005	BRCA2
response to pain	1	443.5×	0.005	RET
regulation of axonogenesis	1	443.5×	0.005	RET
positive regulation of DNA-templated transcription	2	27.9×	0.005	BRCA2, RET
female gonad development	1	401.2×	0.005	BRCA2
neuron maturation	1	401.2×	0.005	RET
hematopoietic stem cell proliferation	1	324.1×	0.006	BRCA2
oocyte maturation	1	300.9×	0.006	BRCA2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
RET	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
RET	135	4
BRCA2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PONATINIB	4	RET
AFATINIB	4	RET
VEMURAFENIB	4	RET
FEDRATINIB	4	RET
TIVOZANIB	4	RET
LENVATINIB	4	RET
AXITINIB	4	RET
SORAFENIB	4	RET
DASATINIB ANHYDROUS	4	RET
ALECTINIB	4	RET
RUXOLITINIB	4	RET
INFIGRATINIB PHOSPHATE	4	RET
INFIGRATINIB	4	RET
IBRUTINIB	4	RET
PALBOCICLIB	4	RET
REGORAFENIB	4	RET
ENTRECTINIB	4	RET
TOFACITINIB CITRATE	4	RET
FOSTAMATINIB	4	RET
CABOZANTINIB	4	RET
BARICITINIB	4	RET
TOFACITINIB	4	RET
CAPIVASERTIB	4	RET
CERITINIB	4	RET
VANDETANIB	4	RET
NILOTINIB	4	RET
BOSUTINIB	4	RET
GILTERITINIB	4	RET
BRIGATINIB	4	RET
UPADACITINIB	4	RET

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
RET	1,586	Binding:1573, Functional:10, ADMET:3

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
RET	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
RET	1,586

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PONATINIB	4	RET
AFATINIB	4	RET
VEMURAFENIB	4	RET
FEDRATINIB	4	RET
TIVOZANIB	4	RET
LENVATINIB	4	RET
AXITINIB	4	RET
SORAFENIB	4	RET
DASATINIB ANHYDROUS	4	RET
ALECTINIB	4	RET
RUXOLITINIB	4	RET
INFIGRATINIB PHOSPHATE	4	RET
INFIGRATINIB	4	RET
IBRUTINIB	4	RET
PALBOCICLIB	4	RET
REGORAFENIB	4	RET
ENTRECTINIB	4	RET
TOFACITINIB CITRATE	4	RET
FOSTAMATINIB	4	RET
CABOZANTINIB	4	RET
BARICITINIB	4	RET
TOFACITINIB	4	RET
CAPIVASERTIB	4	RET
CERITINIB	4	RET
VANDETANIB	4	RET
NILOTINIB	4	RET
BOSUTINIB	4	RET
GILTERITINIB	4	RET
BRIGATINIB	4	RET
UPADACITINIB	4	RET

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	RET
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	BRCA2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 106.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	51
PHASE2	21
PHASE1	16
PHASE1/PHASE2	8
PHASE3	6
PHASE4	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06784986	PHASE4	RECRUITING	Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT03241537	PHASE3	ACTIVE_NOT_RECRUITING	COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer
NCT05622162	PHASE3	ACTIVE_NOT_RECRUITING	Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
NCT00255125	PHASE3	COMPLETED	Role of Soy Supplementation in Prostate Cancer Development
NCT01695135	PHASE3	COMPLETED	A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
NCT01715285	PHASE3	COMPLETED	A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT02380027	PHASE3	COMPLETED	PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?
NCT05137561	PHASE2/PHASE3	COMPLETED	Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)
NCT03173924	PHASE2	ACTIVE_NOT_RECRUITING	18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
NCT03181867	PHASE2	ACTIVE_NOT_RECRUITING	18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NCT03424850	PHASE1/PHASE2	RECRUITING	Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
NCT04045717	PHASE2	ACTIVE_NOT_RECRUITING	Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0
NCT04053842	PHASE2	ACTIVE_NOT_RECRUITING	Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
NCT04633252	PHASE1/PHASE2	RECRUITING	A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
NCT05373316	PHASE2	NOT_YET_RECRUITING	Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy
NCT06957691	PHASE2	RECRUITING	Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
NCT00005916	PHASE2	COMPLETED	PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
NCT00167648	PHASE2	COMPLETED	Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer
NCT00298155	PHASE2	COMPLETED	Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
NCT00425503	PHASE2	COMPLETED	PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
NCT00473746	PHASE1/PHASE2	COMPLETED	Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
NCT00474383	PHASE2	COMPLETED	An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
NCT00544440	PHASE2	COMPLETED	An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
NCT00970203	PHASE2	COMPLETED	Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
NCT01240551	PHASE2	COMPLETED	F-18 Sodium Fluoride in Prostate Cancer
NCT01284920	PHASE1/PHASE2	COMPLETED	A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
NCT01424930	PHASE2	COMPLETED	A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01477749	PHASE2	COMPLETED	Sipuleucel-T Manufacturing Demonstration Study
NCT01630967	PHASE2	UNKNOWN	Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
NCT02582749	PHASE2	TERMINATED	Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
NCT02649855	PHASE2	COMPLETED	Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
NCT03493945	PHASE1/PHASE2	COMPLETED	Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
NCT03531827	PHASE2	TERMINATED	Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
NCT03572387	PHASE2	COMPLETED	A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
NCT03828838	PHASE1/PHASE2	COMPLETED	Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
NCT04019327	PHASE1/PHASE2	COMPLETED	A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
NCT05191017	PHASE1/PHASE2	WITHDRAWN	Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NCT07114601	PHASE1	RECRUITING	A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07583160	PHASE1	ENROLLING_BY_INVITATION	YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ABIRATERONE ACETATE	4	6
DEXTROMETHORPHAN	4	3
THEOPHYLLINE ANHYDROUS	4	3
ABIRATERONE	4	2
FLUDEOXYGLUCOSE F 18	4	2
PIFLUFOLASTAT F18	4	2
DAROLUTAMIDE	4	1
DEGARELIX	4	1
DIPHENHYDRAMINE HYDROCHLORIDE	4	1
DUTASTERIDE	4	1
ENZALUTAMIDE	4	1
GOZETOTIDE	4	1
KETOCONAZOLE	4	1
LEVOKETOCONAZOLE	4	1
OLAPARIB	4	1
RADIUM RA 223 DICHLORIDE	4	1
SIPULEUCEL-T	4	1
TALAZOPARIB	4	1
TRETINOIN	4	1
BINTRAFUSP ALFA	3	2
EPACADOSTAT	3	1
NOGAPENDEKIN ALFA	3	1
RILIMOGENE GALVACIREPVEC	3	1
DAVAMOTECAN PEGADEXAMER	2	1
INBAKICEPT	2	1
VIPIVOTIDE TETRAXETAN	2	1
5-METHYL-2’-FLUOROARAURACIL F-18	1	1
ASG-5ME	1	1
PF-06952229	1	1
CHEMBL15720	0	10